{"links":{"html":"https://www.erudio.com/reports/behold-1-nct06431594","json":"https://www.erudio.com/reports/behold-1-nct06431594.json","markdown":"https://www.erudio.com/reports/behold-1-nct06431594.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"behold-1-06431594"}},"request":"https://www.erudio.com/contact?report=behold-1-06431594"},"offer":{"cited_commentary_sources":24,"verified_hcp_statements":100,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":6,"optional":true,"price_per_verified_person_usd":15,"price_usd":90,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"behold-1-nct06431594"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=behold-1-06431594","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/behold-1-nct06431594","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T11:21:53.103269Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":2},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Part 1: Number of participants with dose limiting toxicity (DLT)"},{"claim_count":16,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":12,"title":"Primary endpoint: Part 2-Confirmed Objective Response Rate (ORR) assessed by investigator"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":21,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":8,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":3,"title":"Durability beyond response rate"},{"claim_count":23,"coverage":"discussed","id":"A2","source_count":13,"title":"B7-H4 target breadth and exploratory response biomarkers"},{"claim_count":12,"coverage":"discussed","id":"A3","source_count":4,"title":"ADC sequencing and individualized treatment niches"},{"claim_count":5,"coverage":"discussed","id":"A4","source_count":2,"title":"BEHOLD-2 immune-combination rationale"},{"claim_count":18,"coverage":"discussed","id":"A5","source_count":9,"title":"Future development, trial access and patient participation"}],"counts":{"cited_sources":25,"claims_by_expression_type":{"comparison":6,"experience":9,"interpretation":19,"opinion":25,"primary_context":4,"question":2,"restatement":23,"uncertainty":6,"unspecified":6},"claims_by_kind":{"interpretation":2,"publication_statement":1,"source_observation":97},"clinician_statements":34,"evidence_units":72,"findings":7,"organisational_accounts":6,"people_cited":13,"people_identity_verified":6,"people_total":13,"screened_sources":36,"verified_claims":100},"findings_index":[{"id":"F1","structure":{"claims":25,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":11,"views":11},"has_counterview":false,"limitations":3,"links":{"context":7,"support":32},"ma_question":true,"named_voices":14,"passages":25,"sources":15,"sources_by_kind":{"commentary":9,"media":5,"publication":1}},"title":"Response enthusiasm supports further development, not established comparative superiority"},{"id":"F2","structure":{"claims":20,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":9,"views":9},"has_counterview":false,"limitations":3,"links":{"context":10,"support":25},"ma_question":true,"named_voices":7,"passages":17,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Favorable safety language must remain attached to dose and supportive-care conditions"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":5,"questions":0,"restated":2,"views":1},"has_counterview":false,"limitations":3,"links":{"context":2,"support":9},"ma_question":true,"named_voices":2,"passages":3,"sources":2,"sources_by_kind":{"media":2}},"title":"Practical implementation centers on prevention, early monitoring and drug-specific counseling"},{"id":"F4","structure":{"claims":23,"claims_by_group":{"comparisons":2,"experience":1,"questions":4,"restated":6,"views":10},"has_counterview":true,"limitations":4,"links":{"context":5,"support":25},"ma_question":true,"named_voices":10,"passages":18,"sources":13,"sources_by_kind":{"commentary":10,"media":3}},"title":"Broad target expression attracts interest, but the predictive biomarker remains unsettled"},{"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":3,"questions":4,"restated":1,"views":3},"has_counterview":false,"limitations":4,"links":{"context":1,"support":12},"ma_question":true,"named_voices":3,"passages":6,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"ADC positioning is conditional on access, prior toxicity and missing sequencing evidence"},{"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":1},"has_counterview":false,"limitations":3,"links":{"context":2,"support":5},"ma_question":true,"named_voices":2,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"The immune-combination argument belongs to BEHOLD-2 and remains a mechanistic hypothesis"},{"id":"F7","structure":{"claims":22,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":7,"views":15},"has_counterview":false,"limitations":4,"links":{"context":3,"support":28},"ma_question":true,"named_voices":8,"passages":18,"sources":8,"sources_by_kind":{"commentary":1,"media":7}},"title":"Trial access is encouraged, but enthusiasm remains preliminary and participation is conditional"}],"medical_affairs_question":"Which phase III and sequencing evidence will distinguish benefit by patient and antigen-expression level, and what supportive-care conditions are needed to interpret tolerability?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Enthusiasm is a development argument, not a superiority conclusion"},{"id":"section-2","level":2,"title":"Dose and prophylaxis qualify the favorable safety reading"},{"id":"section-3","level":2,"title":"Prevention and counseling are part of the implementation burden"},{"id":"section-4","level":2,"title":"Target breadth does not settle what a predictive biomarker should measure"},{"id":"section-5","level":2,"title":"Sequencing and treatment niches remain constrained by access and eligibility"},{"id":"section-6","level":2,"title":"BEHOLD-2 supplies an immune-combination hypothesis, not a BEHOLD-1 outcome"},{"id":"section-7","level":2,"title":"Trial access is an opportunity discussion, not a benefit guarantee"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, sequential, phase1","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Part 1: Number of participants with dose limiting toxicity (DLT)"},{"findings":[{"id":"F1","shared_claims":15},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":2}],"id":"T2","label":"Primary endpoint: Part 2-Confirmed Objective Response Rate (ORR) assessed by investigator"},{"findings":[],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F7","shared_claims":4}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":14},{"id":"F3","shared_claims":8},{"id":"F7","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T11:21:53.103269Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T11:36:12Z","record_hash":"8691f055b5f92166085fce9edbb9cb9a83ebec4fe83a40009896a0d49beb7b6e","release_hash":"503420ddbe145adcbdcc2ea334f802da2207944da9146e264d797f465a1b589f","report_id":"erudio-nct06431594","run_id":"b130bf83-56b3-43b4-9eae-1e81336c6183","schema_version":"5.0","slug":"behold-1-06431594","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"BEHOLD-1 examines mocertatug rezetecan’s safety and activity in advanced solid cancers, including ovarian cancer resistant to platinum and endometrial cancer. Commentary spans X posts, podcasts and YouTube videos, including physicians in surgical oncology. The discussion asks whether response enthusiasm supports further development, how dose and supportive care qualify favorable safety assessments, and whether predictive biomarkers can guide selection. The sources place phase 1 results from BEHOLD-1 at the 2026 SGO Annual Meeting and its translational analysis at ESMO2026.","meta_description":"36 sources screened · 100 verified statements (34 from clinicians verified by NPI or staff page) from 25 sources · 7 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-14c763e8011842736147","claim-4a43a05676f5e40d1531"],"id":"F2","paraphrase":"A podcast discussion asks which mocertatug rezetecan dose will advance to later-phase studies.","publication_caveats":["The sources reviewed for this edition do not establish the speaker’s individual clinical identity or role."],"source_channel":"podcast","source_date":"2026-06-02","title":"Favorable safety language must remain attached to dose and supportive-care conditions"},{"cited_claim_ids":["claim-fe8b33ab73379f17359f","claim-bfa1020f3a3e60865bac"],"id":"F4","paraphrase":"An X post addresses the methodological question of which cathepsin markers to assess in an exploratory analysis of mocertatug rezetecan response.","publication_caveats":["The poster’s clinical role is not established in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":"2026-10-24","title":"Broad target expression attracts interest, but the predictive biomarker remains unsettled"}]},"publication":{"approved_at":"2026-10-31T11:36:12Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":36},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.","Not yet captured in this edition: a question about safety concerns when choosing an alternative antibody–drug conjugate for advanced endometrial cancer.","Not yet captured in this edition: a question about ADC payload selection and community management of payload-related toxicities.","Not yet captured in this edition: a view on prior toxicity-management experience and the lack of focused mitigation strategies in gynecologic oncology.","Not yet captured in this edition: a view on choosing immunotherapy versus an antibody–drug conjugate according to performance status, response urgency and symptomatic disease burden.","Not yet captured in this edition: a view on the tentative comparative positioning of antibody–drug conjugates and their sequencing in advanced gynecologic cancers.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","70 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","This is a selective account of the sources reviewed for this edition, not a representative sample of HCP opinion or evidence of consensus.","The search emphasized BEHOLD-1 and listed drug names. Unnamed references, different transcriptions and discussions that could not be read or fully evaluated may be missing.","Some potentially relevant treatment-selection and counseling passages are not represented in the verified statements available here. A complete account of alternative-ADC counseling or conditional decisions to defer treatment cannot be inferred.","The publication provided is a methods and endpoints description, not a results publication independently validating the response, durability or safety figures discussed. A full protocol and an exact product label were unavailable.","Several results are relayed from presentations or sponsor announcements. Their ownership remains with the attributed party; favorable reporting is not an independent clinical endorsement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A speaker is described in the source as presenting BEHOLD-1. That involvement is source-described and should accompany interpretation of the interview, rather than being treated as an external independent assessment.","Some passages cannot be reliably assigned a speaker name and may be by named participants in the same source. Repeated videos, reposts and organizational relays do not establish additional independent HCP views.","Dose-specific, disease-specific and supportive-care-qualified accounts should not be pooled. Publication or post dates alone do not establish a change of mind, a changed dose decision or improved safety."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":4,"publication":1,"registry":0,"regulatory":0,"x_thread":17,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":24,"context":1},"count":25,"evidence_window":{"end":"2026-10-29","start":"2026-03-19"},"retrieval_snapshot":"2026-10-31T10:11:45.161728Z","timeline":[{"count":1,"week":"2026-W12"},{"count":3,"week":"2026-W15"},{"count":5,"week":"2026-W16"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W28"},{"count":2,"week":"2026-W40"},{"count":1,"week":"2026-W42"},{"count":6,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06431594:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06431594:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42850140","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:979e77","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d1527d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ed115b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f191fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043334291543744554:50dd2a31-96a3-4191-9c4f-1fdd4e8b5575","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043334630506422348:78d53788-8eb1-4bfc-b82e-d07f68d7baf6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043335049282531423:fa8dbd0d-23bf-4b11-8c11-11da3c528171","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043353145082876022:5c4999ea-bc21-46d2-a339-9a36b1734548","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043394664150217162:bef23827-34ec-46a5-aff3-2ecc61a19530","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043534675331649970:f035a570-47c1-4c03-ad15-ea12347bb6f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043634913115517421:106c609f-9b0f-4e43-911f-f43285a1fe23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043793778746458348:d399d486-b16a-4950-85d6-04b1740697dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043854697375904024:3894e2c8-00f2-46f9-abd3-6d85f30a0382","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045857447634719043:523d7aea-7765-4420-87e5-dd1e29d187c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049111628591849635:37e62807-9dd8-4408-ae5a-88b0540f6465","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067053738469269550:01762478-6585-410d-ad0a-57024e7e52a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067324403914866882:5a21b16d-847a-4f7e-b7e7-b197f06dde5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090076962446250084:62131753-ccfb-43ba-966d-cd0806bb6f18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105617042103808267:2d6d94a9-45a3-4ca7-a559-a47d514b9db8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106036105690649061:7ea357cd-1e3e-4bb6-bdaf-0caf80edf5da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112973497345413221:76037b92-92e8-4b4d-ab14-e3c107cca213","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113566049102889208:64bda6d5-55a9-432e-a8c8-4ad507341064","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113889035538350442:7bb57b21-2600-4007-a34b-d30d069fa035","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113890196576145612:599de53e-bad1-4a0a-bb89-d4ed9308781d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113891952508997649:3adeefc0-f8ce-4c75-8d3f-929b40c1c103","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113895114041094581:fe872091-de56-45fa-bb54-8c47ffa043e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113912696827503047:a462d047-7d72-4262-b549-912d94e19c25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113953450669330637:c43ed70c-ec7e-4d9f-974b-1550c4773486","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114039743956623782:72b742ff-f18c-46ca-b7dc-23786e77f4df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114455402981040233:5e60f351-99db-4ed2-a27e-c9792bab69df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114661153376718868:38bba231-fc7f-4771-9908-bac39c83fb9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114817343725490553:bd0016d6-d910-4335-93fb-d08ea5175213","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115783318025179347:272b118d-be82-4811-bbf4-0fc5dd1125dd","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:OMQbahgMAt0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:i1c5DEc1fX0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:jsGsP7OmQQg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":4,"publication":0,"registry":0,"regulatory":0,"x_thread":29,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":36},"count":36,"evidence_window":{"end":"2026-10-29","start":"2026-03-19"},"retrieval_snapshot":"2026-10-31T10:11:45.161728Z","timeline":[{"count":1,"week":"2026-W12"},{"count":5,"week":"2026-W15"},{"count":5,"week":"2026-W16"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W23"},{"count":2,"week":"2026-W25"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W34"},{"count":2,"week":"2026-W40"},{"count":1,"week":"2026-W42"},{"count":11,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: mocertatug rezetecan","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Solid Tumors","status":"unmapped"},{"reason":"Unmapped registry condition: Neoplasms","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"BEHOLD-1","aliases":["BEHOLD-1","A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)","A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors"],"brief_title":"A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Solid Tumors","Neoplasms"],"display_condition":"advanced solid tumors","display_interventions":[["mocertatug rezetecan"]],"enrollment":{"count":675,"type":"ESTIMATED"},"interventions":[{"name":"Mocertatug rezetecan","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06431594","official_title":"A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors","overall_status":"RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2027-09-22","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Part 1: Number of participants with dose limiting toxicity (DLT)","timeFrame":"Up to 21 days"},{"description":"ORR is defined as the proportion of participants with at least one confirmed Complete Response (CR) or Partial Response (PR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)","measure":"Part 2-Confirmed Objective Response Rate (ORR) assessed by investigator","timeFrame":"Up to approximately 28 months"}],"registered_date":{"date":"2024-05-28","type":"ACTUAL"},"registry_last_updated":"2026-06-25","registry_url":"https://clinicaltrials.gov/study/NCT06431594","short_name":"BEHOLD-1","short_name_basis":"canonical_name","sponsor":"GlaxoSmithKline","start_date":{"date":"2024-07-02","type":"ACTUAL"},"study_design":"interventional, randomized, sequential, phase1","study_ids":[{"id":"222730","type":"sponsor_study_id"},{"domain":"CTIS","id":"2024-513860-25","type":"registry"}],"study_type":"INTERVENTIONAL"}}}